Skip to main content
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2017 May 4;10:2425. doi: 10.2147/OTT.S140498

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]

PMCID: PMC5422532  PMID: 28496341

Li X, Song C, Huang G, Sun S, Qiao J, Zhao J, Zhao Z, Li M. The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer. OncoTargets and Therapy. 2017;10:1735–1742.

The authors have advised us of concerns about the specificity of the primary antibody which have resulted in misleading and false results.


Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES